NVIDIA is now an investor in Verily Health. The chipmaker joined an extension of the round Verily opened in March. CU Healthcare Innovation Fund II, already a backer, added more capital. Terms were not disclosed.
The capital goes to Verily Pre, the company’s flagship platform that turns clinical, genomic and device records into AI-ready datasets, and to Verily Me, its patient engagement product. Alphabet, Series X Capital and UCHealth stay on the cap table.
The investment formalizes a collaboration announced in October 2025, when Verily began running NVIDIA’s NeMo, Parabricks and RAPIDS libraries on B200 GPUs. The pair also built Forecast 1.0, a foundation model that fuses genomics with electronic health records to sharpen long-term risk prediction.
“These investments strengthen our ability to pursue the opportunity ahead,” said Stephen Gillett, Verily’s chairman and CEO.
The deal lands as health systems struggle with fragmented records. Verily’s pitch is that model quality depends less on algorithms than on whether data arrives in a usable state. NVIDIA gains a channel into providers buying accelerated computing.
Verily has weathered repeated retrenchment, including a 2025 shutdown of its medical device program. The latest backing suggests investors view the data layer, not hardware, as the durable business.
